Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib in Advanced Salivary Gland Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Disease specific~* locally advanced, recurrent, and/or metastatic SGC (excluding sarcomas and mesenchymal tumors)~* c-MET positive disease~* Measurable disease per RECIST version 1.1 Cohort-specific criteria~* SDC cohort: direct inclusion (no objective tumor growth prior to inclusion needed)~* ACC cohort: inclusion after objective growth in the last three months or complaints due to the disease~* Other SGC's: inclusion after objective growth in the last three months or complaints due to the disease General conditions~* Age ≥18 years~* Eastern Cooperative Oncology Group performance status of 0 or 1.~* Normal number of neutrophils and thrombocytes~* Liver function: ALT and AST \< 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN (except for Gilbert's syndrome), serum albumin ≥28 g/L~* Renal function: creatinine \< 1.5 x ULN or calculated creatinine clearance ≥ 40 ml/min, Urine protein/creatinine ratio ≤113.1 mg/mmol (≤1 mg/mg) or 24-hour urine protein \<1 g~* Hemoglobin A1c (HbA1c) ≤ 8% or a fasting serum glucose ≤ 9 mmol/l~Exclusion Criteria:~General conditions~* A known allergy for cabozantinib or its components~* Long QT-syndrome~* Pregnancy or lactation~* Patients (M/F) with reproductive potential not implementing adequate contraceptives measures~* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before inclusion~* Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before inclusion and from minor surgery at least 10 days before inclusion~* Uncontrolled illness including, but not limited to cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias, uncontrolled hypertension defined as sustained systolic BP \> 150 mm Hg, or diastolic BP \> 100 mm Hg, stroke (including TIA), myocardial infarction, or other ischemic event within 6 months before inclusion, serious active infections Concomitant treatments~* Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation.~* Concurrent treatment with any other anti-cancer therapy.~* Concomitant anticoagulation. Low dose aspirin for cardioprotection and low dose LMWH are permitted.~* Radiation therapy within the last 4 weeks before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cabozantinib (Type: EXPERIMENTAL): cabozantinib 60 mg tablets OD

Based on this trial design, predict the completion outcome and termination type (if applicable).